Prognostic factors in multiple sclerosis

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

I. INTRODUCTION Since the introduction of long-term disease-modifying treatments such as interferon-ß to clinical practice (1) there has been an increasing tendency to initiate treatment early in the course of disease of patients with MS. A need for treatments that act early and over the long term is evident from growing evidence that irreversible axonal damage begins early (2) and disability accumulates over time. However, to maximize the long-term benefit and minimize toxicity of a treatment, physicians should select the right patient at the right stage of disease. Given the short follow-up periods of clinical trials relative to time over which disability develops in MS, the need to demonstrate long-term benefit of these chronic treatments is evident. Especially in the setting of expensive and dedicated treatment strategies, physicians need reliable measures to predict the course and outcome of MS in order to initiate treatment early.

Original languageEnglish (US)
Title of host publicationHandbook of Multiple Sclerosis, Third Edition
PublisherCRC Press
Pages449-463
Number of pages15
ISBN (Electronic)9780824741846
ISBN (Print)9780824704858
StatePublished - Jan 1 2001

Fingerprint

Multiple Sclerosis
Therapeutics
Physicians
Patient Rights
Interferons
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kantarci, O. H., & Weinshenker, B. G. (2001). Prognostic factors in multiple sclerosis. In Handbook of Multiple Sclerosis, Third Edition (pp. 449-463). CRC Press.

Prognostic factors in multiple sclerosis. / Kantarci, Orhun H; Weinshenker, Brian G.

Handbook of Multiple Sclerosis, Third Edition. CRC Press, 2001. p. 449-463.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kantarci, OH & Weinshenker, BG 2001, Prognostic factors in multiple sclerosis. in Handbook of Multiple Sclerosis, Third Edition. CRC Press, pp. 449-463.
Kantarci OH, Weinshenker BG. Prognostic factors in multiple sclerosis. In Handbook of Multiple Sclerosis, Third Edition. CRC Press. 2001. p. 449-463
Kantarci, Orhun H ; Weinshenker, Brian G. / Prognostic factors in multiple sclerosis. Handbook of Multiple Sclerosis, Third Edition. CRC Press, 2001. pp. 449-463
@inbook{59bcc50c38d7422388d8da716f735ba3,
title = "Prognostic factors in multiple sclerosis",
abstract = "I. INTRODUCTION Since the introduction of long-term disease-modifying treatments such as interferon-{\ss} to clinical practice (1) there has been an increasing tendency to initiate treatment early in the course of disease of patients with MS. A need for treatments that act early and over the long term is evident from growing evidence that irreversible axonal damage begins early (2) and disability accumulates over time. However, to maximize the long-term benefit and minimize toxicity of a treatment, physicians should select the right patient at the right stage of disease. Given the short follow-up periods of clinical trials relative to time over which disability develops in MS, the need to demonstrate long-term benefit of these chronic treatments is evident. Especially in the setting of expensive and dedicated treatment strategies, physicians need reliable measures to predict the course and outcome of MS in order to initiate treatment early.",
author = "Kantarci, {Orhun H} and Weinshenker, {Brian G}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824704858",
pages = "449--463",
booktitle = "Handbook of Multiple Sclerosis, Third Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Prognostic factors in multiple sclerosis

AU - Kantarci, Orhun H

AU - Weinshenker, Brian G

PY - 2001/1/1

Y1 - 2001/1/1

N2 - I. INTRODUCTION Since the introduction of long-term disease-modifying treatments such as interferon-ß to clinical practice (1) there has been an increasing tendency to initiate treatment early in the course of disease of patients with MS. A need for treatments that act early and over the long term is evident from growing evidence that irreversible axonal damage begins early (2) and disability accumulates over time. However, to maximize the long-term benefit and minimize toxicity of a treatment, physicians should select the right patient at the right stage of disease. Given the short follow-up periods of clinical trials relative to time over which disability develops in MS, the need to demonstrate long-term benefit of these chronic treatments is evident. Especially in the setting of expensive and dedicated treatment strategies, physicians need reliable measures to predict the course and outcome of MS in order to initiate treatment early.

AB - I. INTRODUCTION Since the introduction of long-term disease-modifying treatments such as interferon-ß to clinical practice (1) there has been an increasing tendency to initiate treatment early in the course of disease of patients with MS. A need for treatments that act early and over the long term is evident from growing evidence that irreversible axonal damage begins early (2) and disability accumulates over time. However, to maximize the long-term benefit and minimize toxicity of a treatment, physicians should select the right patient at the right stage of disease. Given the short follow-up periods of clinical trials relative to time over which disability develops in MS, the need to demonstrate long-term benefit of these chronic treatments is evident. Especially in the setting of expensive and dedicated treatment strategies, physicians need reliable measures to predict the course and outcome of MS in order to initiate treatment early.

UR - http://www.scopus.com/inward/record.url?scp=85056678797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056678797&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056678797

SN - 9780824704858

SP - 449

EP - 463

BT - Handbook of Multiple Sclerosis, Third Edition

PB - CRC Press

ER -